On November 26, at the award ceremony of the inaugural China Pharmaceutical Listed Companies Value Management Summit held in Beijing, The United Laboratories International Holdings Limited (3933.HK) was recognized for its outstanding performance in ESG transparency, ESG governance, and materiality management. The Company was listed among the “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness in 2025”and received the certificate of “Top 20 Most Competitive Chinese Pharmaceutical Listed Companies 2025.”

The evaluation was jointly initiated by E-Pharma Managers and Shangdao Consulting, focusing on core dimensions such as ESG transparency and management performance, and serves as an authoritative ranking of ESG management practices in China’s pharmaceutical sector. Being listed highlights the strong recognition from both the capital market and professional institutions of United Laboratories’ sustainable development strategy.

TUL will continue to be innovation-driven and responsibility-focused, further deepening ESG management and practices, and working together with industry partners to promote high-quality and sustainable development in China’s pharmaceutical industry.